RAD51 and neoplasm: A second oncologic implication is that the balance of RAD51-RAD54 activities may represent a drug target for cancer treatment because tumor cells expressing high levels of RAD51 may prove to be differentially sensitive to compounds such as streptonigrin that inhibit RAD54 (78).